Table 1.

summarizes the aluminum content of temporal lobe neocortical tissues from 16 neurological diseases, a young control group (YCG), and an aged control group (ACG) analyzed in this study. N, number of individual brains examined; S.D., one standard deviation; range, lowest to highest aluminum signal quantified; the mean age (year) ± S.D. is the mean of the age of individual patients afflicted with each neurological disease plus one standard deviation of that mean; *p < 0.0001 ANOVA; p, significance; ANOVA, analysis of variance; S, significant; NS, not significant; NA, not applicable

Abbreviation	Neurological disease	Al, μg/g dry weight
		N	Mean	S. D.	Range	p, ANOVA	S or NS	Mean age (year) ± S.D.
AD	Alzheimer’s disease	186	8.08	2.91	1.9–16.8	< 0.0001	S	73.1 ± 15.6
AFT	Ataxia-Friedreich’s type	6	1.15	0.18	0.9–1.4	1	NS	69.3 ± 11.5
ALS	Amyotrophic lateral sclerosis	16	1.22	0.14	0.95–1.4	1	NS	67.5 ± 10.1
ASD	Autism spectrum disorder	26	1.22	0.2	0.9–1.6	1	NS	11.1 ± 6.4
DDS	Dialysis dementia syndrome	27	3.69	1.14	1.2–6.2	< 0.0001	S	72.4 ± 13.2
DS	Down’s syndrome (trisomy 21)	24	4.53	1.18	2.0–7.1	< 0.0001	S	75.3 ± 9.3
HC	Huntington’s chorea	15	1.69	0.9	0.3–3.1	1	NS	70.4 ± 14.3
MID	Multiple infarct dementia	19	1.35	0.31	1.0–2.1	1	NS	70.4 ± 10.3
MS	Multiple sclerosis	23	1.37	0.43	0.7–2.1	1	NS	71.5 ± 9.3
PD	Parkinson’s disease	27	1.77	0.76	0.4–3.2	0.9998	NS	72.5 ± 10.1
PrD	Prion disease (BSE, CJD, GSS)	11	1.31	0.34	0.9–2.1	1	NS	74.2 ± 9.8
PML	Progressive multifocal leukoencephalopathy	11	1.5	0.56	0.7–2.3	1	NS	73.1 ± 16.3
PSP	Progressive supranuclear palsy	24	1.45	0.4	0.5–2.3	1	NS	71.9 ± 14.4
SCZ	Schizophrenia	21	1.74	0.56	0.9–1.5	1	NS	69.3 ± 11.6
YCG	Young control group	22	1.2	1.19	0.9–1.5	NA	NA	10.2 ± 6.1
ACG	Aged control group	53	1.34	1.34	0.16–1.8	NA	NA	71.4 ± 9.3